Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -271.5%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $360486 | $4M | $1M | $4M | $9M | $7M | $5M | $5M | $7M | $7M | $7M |
| Enterprise Value | $9M | $12M | $25M | $21M | $7M | $13M | $13M | $4M | $6M | $4M | $8M |
| P/E Ratio → | -0.04 | — | — | — | 0.47 | 0.90 | — | — | — | 0.17 | — |
| P/S Ratio | 0.08 | 0.88 | 0.21 | 0.09 | 0.07 | 0.08 | 0.37 | 0.46 | 0.55 | 0.69 | 0.33 |
| P/B Ratio | 0.18 | 1.09 | 0.20 | 0.08 | 0.14 | 0.11 | 0.50 | 0.41 | 0.44 | 0.21 | 1.15 |
| P/FCF | — | — | — | — | 0.36 | — | — | — | — | — | — |
| P/OCF | — | — | — | — | 0.31 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.84 | 3.74 | 0.47 | 0.06 | 0.16 | 0.91 | 0.42 | 0.43 | 0.37 | 0.38 |
| EV / EBITDA | — | — | — | — | 0.24 | 0.87 | — | — | — | — | — |
| EV / EBIT | — | — | — | — | 0.29 | 1.99 | — | — | — | — | — |
| EV / FCF | — | — | — | — | 0.28 | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 31.9% | 31.9% | -2.2% | 36.6% | 57.6% | 41.5% | 31.7% | 26.5% | 36.4% | 19.7% | 47.9% |
| Operating Margin | -415.4% | -415.4% | -570.6% | -48.7% | 19.2% | 12.4% | -27.4% | -32.8% | -12.4% | -40.4% | -12.6% |
| Net Profit Margin | -339.3% | -339.3% | -788.2% | -37.8% | 15.1% | 7.9% | -14.6% | -31.9% | -13.3% | 423.9% | -13.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -271.5% | -271.5% | -188.1% | -29.7% | 30.2% | 18.1% | -19.5% | -22.7% | -7.2% | 221.3% | -38.8% |
| ROA | -24.0% | -24.0% | -68.8% | -18.7% | 20.9% | 10.4% | -9.7% | -19.1% | -6.3% | 178.1% | -20.8% |
| ROIC | -62.5% | -62.5% | -59.4% | -25.4% | 28.0% | 17.6% | -20.4% | -18.9% | -5.6% | -16.8% | -25.5% |
| ROCE | -95.3% | -95.3% | -75.6% | -30.3% | 32.5% | 19.8% | -21.8% | -23.3% | -6.7% | -20.8% | -32.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.46 | 2.46 | 3.34 | 0.37 | 0.11 | 0.25 | 1.39 | — | — | — | 0.25 |
| Debt / EBITDA | — | — | — | — | 0.24 | 1.01 | — | — | — | — | — |
| Net Debt / Equity | — | 2.43 | 3.25 | 0.34 | -0.03 | 0.11 | 0.75 | -0.04 | -0.09 | -0.10 | 0.18 |
| Net Debt / EBITDA | — | — | — | — | -0.07 | 0.42 | — | — | — | — | — |
| Debt / FCF | — | — | — | — | -0.09 | — | — | — | — | — | — |
| Interest Coverage | -2.37 | -2.37 | -11.64 | -16.88 | 30.98 | 5.62 | -6.84 | — | — | -73.89 | -17.81 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.06 | 0.06 | 0.95 | 2.28 | 3.78 | 3.95 | 2.52 | 10.66 | 4.31 | 15.96 | 1.41 |
| Quick Ratio | 0.06 | 0.06 | 0.92 | 2.17 | 3.54 | 3.65 | 2.04 | 9.10 | 3.86 | 15.11 | 1.01 |
| Cash Ratio | 0.00 | 0.00 | 0.02 | 0.23 | 1.08 | 1.13 | 1.34 | 1.46 | 1.95 | 12.11 | 0.06 |
| Asset Turnover | — | 0.07 | 0.11 | 0.48 | 1.40 | 0.89 | 0.46 | 0.80 | 0.63 | 0.29 | 1.64 |
| Inventory Turnover | 42.30 | 42.30 | 6.05 | 12.29 | 13.08 | 10.05 | 3.26 | 4.98 | 4.39 | 5.17 | 4.00 |
| Days Sales Outstanding | — | 129.03 | 1081.41 | 294.52 | 110.27 | 174.13 | 79.34 | 252.13 | 216.84 | 71.95 | 100.22 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | 100.0% | 68.8% | — | 100.0% | 100.0% | — | — |
| Payout Ratio | — | — | — | — | 50.7% | 72.5% | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 211.6% | 111.4% | — | — | — | 596.8% | — |
| FCF Yield | — | — | — | — | 274.0% | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 100.0% | 100.0% | 13.9% | 0.0% | 0.0% | 0.0% | 100.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 100.0% | 100.0% | 82.7% | 0.0% | 100.0% | 100.0% | 100.0% | 0.0% |
| Shares Outstanding | — | $8M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $2M | $2M |
Imminent liquidity and insolvency
According to recent market data, ProPhase Labs trades at a price-to-sales multiple of 0.10, which, when compared to the broader specialty pharmaceutical sector, suggests that investors are heavily discounting the company's future revenue potential due to the rapid erosion of its core diagnostic testing business.
The absence of a positive P/E ratio and the extremely low P/B of 0.22 indicate that the market is pricing the firm as a distressed asset rather than a growth-oriented genomics player. This valuation level implies that the market expects significant further contraction or a dilutive capital event to address the current cash shortfall.
As reported in financial statements, the company's ROIC has trended into deep negative territory, reaching -32.8% in 2025Q4, which highlights a severe inability to generate returns on invested capital as the firm struggles to pivot its business model away from legacy diagnostic services.
The consistent decay in ROIC over the last ten quarters suggests that the capital deployed into laboratory infrastructure and genomic acquisitions is failing to produce adequate economic value. This trend warrants investigation into whether the current asset base can ever achieve the scale necessary to reach a positive return threshold.
Based on reported figures, the company's cash conversion cycle has exhibited extreme volatility, swinging from positive 944 days in 2023Q4 to negative 4383 days in 2025Q4, which suggests significant instability in the firm's ability to manage its receivables and payables effectively in a post-pandemic environment.
The massive fluctuations in DSO and DPO indicate that the company's working capital is highly sensitive to the timing of insurance reimbursements and supplier payments. Such instability makes it difficult to forecast cash availability and suggests that operational efficiency is currently secondary to basic survival.
According to recent balance sheet filings, the debt-to-equity ratio has surged to 2.46 as of 2025Q4, reflecting a concerning increase in financial leverage that appears to be driven by the necessity to fund ongoing operating losses rather than strategic growth or capital expansion initiatives.
The lack of positive EBITDA makes traditional interest coverage metrics effectively meaningless, signaling that the company's debt service capacity is severely compromised. Investors should monitor the firm's ability to refinance these obligations, as the current leverage profile leaves little room for error in a high-rate environment.
The price-to-sales ratio is frequently misapplied to ProPhase Labs, as it obscures the company's critical liquidity crisis by suggesting that revenue scale is the primary driver of value, when in reality, the firm's immediate survival depends on cash runway rather than top-line growth.
Using P/S to value this business ignores the fact that a significant portion of revenue may be tied to low-margin or non-recurring diagnostic activities that do not contribute to cash flow. A more appropriate focus would be the cash burn rate relative to available liquidity, which provides a clearer picture of the company's near-term insolvency risk.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PRPH stock.
ProPhase Labs, Inc.'s current P/E ratio is -0.0x. The historical average is 15.0x.
ProPhase Labs, Inc.'s return on equity (ROE) is -271.5%. The historical average is -17.5%.
Based on historical data, ProPhase Labs, Inc. is trading at a P/E of -0.0x. Compare with industry peers and growth rates for a complete picture.
ProPhase Labs, Inc. has 31.9% gross margin and -415.4% operating margin.